|
Scientific
Advisory Council |
|
Jay Boniface
jbonifac@prolexys.com
Dr. Boniface is currently Senior Director of Protein Science at
Prolexys
and prior to that was Director of the Protein Science and Mass
Spectrometry at Myriad Genetics. He was previously employed by Eos
Biotechnology, as Head of their Proteomics laboratory. Dr. Boniface has
extensive experience in the fields of protein biochemistry, protein
chemistry, biomolecular interaction analysis, mass spectrometry and
classical biophysical approaches to the study of protein
structure/function relationships. He has additional experience in protein
expression, the creation and maintenance of cell lines, culture of primary
cells, protein/DNA arrays and microchip instrumentation for the analysis
of cell states. He has authored over 25 scientific papers, reviews and
book chapters. Dr. Boniface earned his BS in Biochemistry from the
University of Massachusetts at Amherst and his PhD in Biochemistry was
awarded by the Albany Medical College, where he received the Leonard Procita Award for the Most Outstanding Research. He also completed a
Postdoctoral Scholarship in Immunology at Stanford University in the
Laboratory of Dr. Mark Davis.
Chris Dambrowitz,
Executive Director of the Canadian Proteome Society
Dambrowitz@proteome.org
Chris Dambrowitz's doctoral research in molecular biology & genetics,
developing transcriptome analysis and genotyping techniques, was
completed in Dr. Norm Dovichi's analytical chemistry laboratory at the
University of Alberta. This group's contributions to ultrasensitive
bioanalytical instrumentation development include the multicapillary DNA
sequencing technology commercialized as the ABI PRISM 3700 DNA Analyzer.
In a post-doctoral position in Chemistry at the University of
Washington, he initiated research efforts in methylomics and microbial
genomics, complementing other group projects in proteomics and
single-cell analysis. In addition to research positions with Atomic
Energy of Canada Limited, his industry experience includes technology &
business development roles with Blue Heron Biotechnology and Visible
Genetics (now owned by Bayer). He is presently the Project Manager for
Genome Prairie's Enabling Technologies
(ET) Project - a Genome Canada project linking research
groups from five Canadian universities and two industrial partners to create
innovative tools extending the bioanalytical capabilities of scientists in the
fields of genomics and proteomics. These include high performance mass
spectrometry products, as well as products based on emerging microfluidic
technologies. Chris is located at the ET Project office at MDS Sciex in Toronto
and will serve as the Canadian Proteome Society Director for 2005.
David Robinson Goodlett
goodlett@u.washington.edu
Dr Goodlett is an Associate professor in the Medicinal Chemistry
department at the University of Washington. He holds an affiliate
faculty appointment at the Institute for Systems Biology where he
administers two exploratory grants. At the University of Washington he
is director of a mass spectrometry core for a National Institute of
Allergy and Infectious Disease grant studying gram negative organisms
having potential as bioterrorism agents and a proteomics core for a
National Institute of Environmental Health Sciences program on
Ecogenetics and Environmental Health. He directs a research program that
is developing proteomic separation and mass spectrometric methods that
are being applied to problems in prostate cancer, acute respiratory
distress syndrome, gram negative bacteria and pediatric medulloblastomas.
The ideas and accomplishments of he and his colleagues have been
communicated through ~ 100 lectures world-wide, over 60 manuscripts and
several patents/filings. His work covers fields from reproductive
physiology, prostate cancer, microbiology, organic synthesis, enzymology,
fundamentals of electrospray ionization, separation science, mass
spectrometric methods and proteomics. In addition to work for the
Proteome Society he is an associate editor at Chromatographia,
Combinatorial Chemistry and High Throughput Screening and Systems
Biology. He serves on the scientific advisory board for two Seattle
based companies, Intelligent Ion Inc. and Insilicos L.L.C., and Dr
Richard Smith’s National Center for Research Resources Proteomics
facility. He also serves the National Institutes of Health on an ad
hoc basis to review grants and is a founding member of the council
for the US chapter of the Human Proteome Organization, US-HUPO.
Previous to his current position at the University of
Washington Dr. Goodlett was employed by the Institute for Systems
Biology where he was hired by Dr. Leroy Hood in the spring
of 2000 to establish their Proteomics laboratory. During his time at the
ISB he worked with colleagues to perfect the isotope code affinity tag
method for pair-wise comparison of proteomes. Prior to joining the ISB,
he took a sabbatical from the pharmaceutical industry to work as a
visiting scientist with Dr. Ruedi Aebersold in the
department of Molecular Biotechnology at the University of Washington.
During this time he developed sensitive analytical methods for detection
and sequencing of phosphopeptides. While employed in the pharmaceutical
industry he carried out analytical research on an HIV therapeutic for
Johnson & Johnson, Inc. and drug discovery research in the field of
immunology, specifically antigen presentation by MHC’s, for
Bristol-Myers Squibb, Inc. He was a NORCUS post-doctoral fellow with
Dr. Richard D. Smith at Battelle-Memorial Institute where he
developed mass spectrometric methods for determination of thermodynamic
properties of non-covalently associated protein-protein complexes and
fundamental studies in capillary electrophoresis-mass spectrometry. He
obtained a Ph.D. in biochemistry from North Carolina State University in
the protein mass spectrometry laboratory of Dr. Richard B. van
Breemen now at University of Illinois Chicago and biochemistry
laboratory of Dr. Frank Armstrong now emeritus faculty. He
holds M.S. & B.S. degrees in chemistry from Auburn University where he
worked under the guidance of Drs. John Aull, Harlow Daron
and Frank Bartol.
Helen Kim
helen.kim@ccc.uab.edu
Dr. Helen Kim
received a Ph.D. in Biophysics from the University of
Virginia, working in the laboratories of Drs. Lionel Rebhun (Virginia)
and Joel Rosenbaum (Yale University). She is
now Director of the 2-D Proteomics
Laboratory, within the Comprehensive Cancer Center Mass Spectrometry
Shared Facility at the University of Alabama at Birmingham (UAB).
Her primary appointment is Associate Professor in the Department of Pharmacology & Toxicology. Dr. Kim studied
the protein biochemistry of
brain microtubules for her
dissertation work. This has evolved to her current focus
on microtubule- and other neural protein modifications that contribute
to the development of neurodegenerative conditions such as Alzheimer's disease, and the protection against such
events by non-nutrient dietary components
high in anti-oxidant activity, such as the soy isoflavones or grape proanthocyanins. She is one of the first
to apply proteomics approaches
to the study of protein changes induced by dietary interventions in
the brain or other mammalian tissues.
Joshua LaBaer
josh@hms.harvard.edu
Dr. LaBaer is the Director of the
Institute of Proteomics at Harvard Medical School. He attended the
University of California at Berkeley for his undergraduate, where he was
awarded the University Medal for the Most Distinguished Graduating
Senior. His studies continued at the University of California, San
Francisco where he attended medical and graduate school and where he
studied steroid regulation of DNA transcription and protein-DNA
interactions with Dr. Keith Yamamoto. Dr LaBaer completed his clinical
training at the Brigham and Women's Hospital in Boston, where he
specialized in internal medicine and the Dana-Farber Cancer Institute in
Boston, where he studied medical oncology. He also pursued research
interests at the Massachusetts General Hospital in Boston in the areas
of breast cancer, mammalian cell cycle regulation and cell cycle
checkpoint genes. He is currently an Attending Physician at the
Dana-Farber Cancer Institute and holds an academic appointment through
the Department of Biological Chemistry and Molecular Pharmacology at
Harvard Medical School. Together with Dr. Ed Harlow, Dr. LaBaer founded
the Harvard Institute of Proteomics in the spring of 1999. The mission
of the Institute is to use the information arising from the genome
projects to revolutionize the study of proteins and their functions by
enabling scientists to produce and study proteins hundreds or thousands
at a time.
Kelvin
Lee
khlee@cheme.cornell.edu
Dr. Lee is an Assistant Professor in the School of Chemical Engineering and in the Field of Biomedical Engineering at Cornell
University. His research program involves three general areas: 1) the
development of new technology for proteome analysis, 2) the application
of existing technologies to the study of protein secretion and in the
diagnosis of neurodegenerative diseases, and 3) a quantitative
understanding of the relationship between mRNA and protein expression
profiles in bacterial cells.
Hercules Moura
hxm3@cdc.gov
Salvatore
Sechi, PhD
SechiS@EXTRA.NIDDK.NIH.GOV
Dr. Salvatore Sechi received his Ph.D. in biochemistry from
the University of Padua in
Italy in 1987. He joined the National Institute of Health as a visiting fellow in 1990
where he was trained in protein chemistry.
During this period, he contributed to the cloning of several novel genes and has patented several
unique methods for protein sequence analysis.
In 1995, he joined as research associate the laboratory of
mass spectrometry headed
by Dr. Brian T. Chait at the Rockefeller University. During
this time, Dr. Sechi improved the methodology of protein identification
by peptide mapping showing that cysteine containing peptides
could be identified using deuterium labeling. In 1998/99, he
was appointed principal investigator in the proteomic laboratory at Dupont and visiting professor in
methodology in biochemistry at the
University of Padua. In 2000 he was appointed head of the mass spectrometry unit at NIA and recently
director of the proteomic program in
the Division of Diabetes, Endocrinology, and Metabolic Diseases at NIDDK.
Kamala Tyagarajan
kamala@guavatechnologies.com
Dr. Tyagarajan is Group Leader for Applications at Guava Technologies.
Formerly, she was a Senior Scientist in
the Proteomics Group at Lynx Therapeutics working on the development of
the Protein ProFiler™: a 2D liquid electrophoresis system for proteome
separation. She specializes in protein chemistry and
protein-identification strategies using mass spectrometry. Prior to
Lynx, Dr. Tyagarajan did her postdoctoral work at UC Berkeley working on
a joint collaboration with the UCSF Mass Spectrometry Facility. She
received her PhD in Biophysical Chemistry from the
University of California at Berkeley.
John Yates,
III
jyates@scripps.edu
Dr. Yates received his PhD in Chemistry at the University of Virginia
under Professor Donald Hunt. His graduate research involved the development and application of tandem mass spectrometry for sequence
analysis of proteins. Following a Biotechnology Fellowship in the laboratory of Professor Leroy Hood at the California Institute of Technology, he moved to the Department of Molecular
Biotechnology at the University of Washington where he attained the rank of Associate
Professor. He is now an Associate Professor in the Department of Cell
Biology at The Scripps Research Institute and Director of Protein
and Metabolite Dynamics at the Novartis Agricultural Discovery Institute in La Jolla, California. His research interests include
development of integrated methods for tandem mass spectrometry analysis of protein mixtures, bioinformatics using mass spectrometry data,
and proteomics. He is co-developer of the SEQUEST software for correlating tandem mass spectrometry data to sequences in the database. He has received the American Society for Mass Spectrometry research
award, the Pehr Edman Award in Protein Chemistry, and has published over 100 scientific articles.
|
|